We can only speculate that hypoxia- and microenvironment-induced (over)expression of BCL-XL may be responsible for survival of venetoclax-resistant lymphoma clones, and conversely that co-targeting BCL-XL and BCL2 may prove synergistic in vivo. Here, BCL2 is linked to lymphoma.